Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Safety and efficacy in a multicenter cohort

Gastric Cancer

Volumn 17, Issue 2, 2014, Pages 341-347

  Pernot, Simon ^a   Mitry, Emmanuel ^b   Samalin, Emmanuelle ^c   Dahan, Laetitia ^e   Dalban, Cécile ^f   Ychou, Marc ^c   Seitz, Jean François ^e   Turki, Hajer ^e   Mazard, Thibault ^d   Zaanan, Aziz ^a   Lepère, Céline ^a   Vaillant, Jean Nicolas ^a   Landi, Bruno ^a   Rougier, Philippe ^a   Taieb, Julien ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSTITUT CURIE   (France)

^c CENTRE VAL D AURELLE   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f CLCC Georges Francois Leclerc   (France)

Author keywords

Docetaxel; Gastric cancer; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX; TAXOID;

ADENOCARCINOMA; AGED; CANCER STAGING; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 84898794565     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0266-6     Document Type: Article

References (21)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-9. (Pubitemid 46630593)
2. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v50-4.
3. Webb A, CunninghamD, Scarffe JH, Harper P, NormanA, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-7. (Pubitemid 27020582)
4. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80(1-2):269-72. (Pubitemid 29210117)
5. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996-2004. (Pubitemid 34413593)
6. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer. 1994;30A(9):1263-9. (Pubitemid 24322059)
7. Mitry E, Taieb J, Artru P, Boige V, Vaillant JN, Clavero-Fabri MC, et al. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol. 2004;15(5):765-9. (Pubitemid 38720157)
8. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-73.
9. Rougier P, Oba K. Meta-analyses of randomized trials assessing the interest chemotherapy in advanced gastric cancer. J Clin Oncol. 2008;26:May 20 suppl; abstr 4563.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7. (Pubitemid 46631401)
11. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25(22): 3205-9. (Pubitemid 47333732)
12. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
13. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-42.
14. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
15. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011;254(5):684-93.
16. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010;116(6):1446-53.
17. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102(3):475-81.
18. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/ fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18(10):1673-9. (Pubitemid 47506254)
19. Van Cutsem E, Boni C, Tabernero J, Massuti B, Richards DA, Prenen H, et al. Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. J Clin Oncol. 2011; suppl. abstr 4018.
20. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882-7.
21. Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65 +). Eur J Cancer. 2012; Epub ahead of print.